$GILD News Speculators should retain a flexible
Post# of 89114
Posted On: 12/10/2013 1:07:11 PM
$GILD News
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt
Gilead (GILD) Shows Signs Of Being Water-Logged And Getting Wetter 34 min ago - TheStreet.com
Gilead CEO's $21 Million Stock Sale 12:04 p.m. Today - Barrons.com
5 Stocks Underperforming Today In The Drugs Industry 12:04 p.m. Today - TheStreet.com
Geron's Game-Changing Myelofibrosis Drug Story Has a Familiar Feel 11:09 a.m. Today - TheStreet.com
Gilead Sciences Inc Stock Buy Recommendation Reiterated (GILD) 9:00 a.m. Today - TheStreet.com
Jakafi competition still a ways off: Canaccord 8:11 a.m. Today - Seeking Alpha
Gilead Sciences: Sovaldi Hepatitis C Pill Approved 6:25 p.m. Dec. 9, 2013 - Seeking Alpha
FDA Clears Gilead's Sovaldi - Analyst Blog 5:00 p.m. Dec. 9, 2013 - Zacks.com
Weekly CEO Sells Highlight: OCZ Technology Group Inc, Workday Inc, Gilead Sciences Inc, Natus ... 4:14 p.m. Dec. 9, 2013 - GuruFocus.com
Today's Market: Deals And News Impacting These Companies 12:59 p.m. Dec. 9, 2013 - Seeking Alpha
Gilead Sciences: A Unique Stallion 11:12 a.m. Dec. 9, 2013 - Seeking Alpha
Celgene, Infinity Rise On Blood Cancer Drug Data 10:24 a.m. Dec. 9, 2013 - Investors Business Daily
Gilead reports data for investigational blood cancer drugs 7:57 a.m. Dec. 9, 2013 - Seeking Alpha
Gilead (GILD) Off To A Strong Start In Pre-Market Activity 7:53 a.m. Dec. 9, 2013 - TheStreet.com
The Numbers Backing Gilead's Best and Fastest Drug Launch in History 6:31 a.m. Dec. 9, 2013 - TheStreet.com
Gilead Announces Phase 2 Study Results for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma at ASH 5:36 p.m. Dec. 8, 2013 - benzinga.com
Gilead Reports Positive Data from Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia 7:03 p.m. Dec. 7, 2013 - benzinga.com
FDA Approves Gilead's Hepatitis C Drug 6:53 p.m. Dec. 6, 2013 - WSJ.com
Not Your Father's Diagnostics: Ram Selvaraju On How Molecular Genomics Invigorate The Sector 4:27 p.m. Dec. 6, 2013 - Seeking Alpha
Gilead Potential Blockbuster Hep C Drug Wins FDA Nod 4:22 p.m. Dec. 6, 2013 - Investors Business Daily
Interest Stock Analysis: Gilead Sciences, Acura Pharmaceuticals, Barnes & Noble, Micron Technology 11:00 a.m. Dec. 9, 2013 - ACCESSWIRE
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma 8:00 a.m. Dec. 9, 2013 - PR Newswire
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 6:00 p.m. Dec. 8, 2013 - BusinessWire
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia 6:30 p.m. Dec. 7, 2013 - BusinessWire
U.S. Food and Drug Administration Approves Gilead's Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 4:19 p.m. Dec. 6, 2013 - BusinessWire
Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3 5:00 p.m. Dec. 2, 2013 - BusinessWire
Critical Alerts For General Electric, Gilead Sciences, Morgan Stanley, Qualcomm, and Adobe Released By InvestorsObserver 9:31 a.m. Dec. 2, 2013 - PR Newswire
Market Expert Opinion: Gilead Sciences, NPS Pharma, InterMune, and Halozyme Therapeutics 8:40 a.m. Dec. 2, 2013 - PR Newswire
Gilead Sciences, Inc. Uses the PHT Corporation LogPad(R) System for 1st Antianginal Drug to Treat Type 2 Diabetes 8:00 a.m. Dec. 2, 2013 - BusinessWire
Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits Against Gilead Sciences 7:00 a.m. Dec. 2, 2013 - GlobeNewswire
Early Morning Buzz: Groupon, Gilead Sciences, Eltek Ltd, Alcatel Lucent SA 9:47 a.m. Nov. 27, 2013 - ACCESSWIRE
Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare 8:00 a.m. Nov. 27, 2013 - PR Newswire
Clinical Studies, Convertible Senior Notes, and Commercial Supply Contracts - Research Report on Gilead, Hologic, Regeneron, OPKO, and Unilife 8:00 a.m. Nov. 25, 2013 - PR Newswire
European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi(R) for the Treatment of Chronic Hepatitis C Infection 8:47 a.m. Nov. 22, 2013 - BusinessWire
Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb, HCA, Allergan, and Alexion 8:00 a.m. Nov. 20, 2013 - PR Newswire
Gilead's Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study 9:17 a.m. Nov. 18, 2013 - BusinessWire
European Commission Approves Gilead's Vitekta(TM), an Integrase Inhibitor for the Treatment of HIV-1 Infection 8:00 a.m. Nov. 18, 2013 - BusinessWire
Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13 4:31 p.m. Nov. 12, 2013 - BusinessWire
Insider Trading Reports for Facebook, Microsoft, Gilead Sciences, Bank of America, Riverbed, and Wells Fargo 8:55 a.m. Nov. 11, 2013 - PR Newswire
S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt
Gilead (GILD) Shows Signs Of Being Water-Logged And Getting Wetter 34 min ago - TheStreet.com
Gilead CEO's $21 Million Stock Sale 12:04 p.m. Today - Barrons.com
5 Stocks Underperforming Today In The Drugs Industry 12:04 p.m. Today - TheStreet.com
Geron's Game-Changing Myelofibrosis Drug Story Has a Familiar Feel 11:09 a.m. Today - TheStreet.com
Gilead Sciences Inc Stock Buy Recommendation Reiterated (GILD) 9:00 a.m. Today - TheStreet.com
Jakafi competition still a ways off: Canaccord 8:11 a.m. Today - Seeking Alpha
Gilead Sciences: Sovaldi Hepatitis C Pill Approved 6:25 p.m. Dec. 9, 2013 - Seeking Alpha
FDA Clears Gilead's Sovaldi - Analyst Blog 5:00 p.m. Dec. 9, 2013 - Zacks.com
Weekly CEO Sells Highlight: OCZ Technology Group Inc, Workday Inc, Gilead Sciences Inc, Natus ... 4:14 p.m. Dec. 9, 2013 - GuruFocus.com
Today's Market: Deals And News Impacting These Companies 12:59 p.m. Dec. 9, 2013 - Seeking Alpha
Gilead Sciences: A Unique Stallion 11:12 a.m. Dec. 9, 2013 - Seeking Alpha
Celgene, Infinity Rise On Blood Cancer Drug Data 10:24 a.m. Dec. 9, 2013 - Investors Business Daily
Gilead reports data for investigational blood cancer drugs 7:57 a.m. Dec. 9, 2013 - Seeking Alpha
Gilead (GILD) Off To A Strong Start In Pre-Market Activity 7:53 a.m. Dec. 9, 2013 - TheStreet.com
The Numbers Backing Gilead's Best and Fastest Drug Launch in History 6:31 a.m. Dec. 9, 2013 - TheStreet.com
Gilead Announces Phase 2 Study Results for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma at ASH 5:36 p.m. Dec. 8, 2013 - benzinga.com
Gilead Reports Positive Data from Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia 7:03 p.m. Dec. 7, 2013 - benzinga.com
FDA Approves Gilead's Hepatitis C Drug 6:53 p.m. Dec. 6, 2013 - WSJ.com
Not Your Father's Diagnostics: Ram Selvaraju On How Molecular Genomics Invigorate The Sector 4:27 p.m. Dec. 6, 2013 - Seeking Alpha
Gilead Potential Blockbuster Hep C Drug Wins FDA Nod 4:22 p.m. Dec. 6, 2013 - Investors Business Daily
Interest Stock Analysis: Gilead Sciences, Acura Pharmaceuticals, Barnes & Noble, Micron Technology 11:00 a.m. Dec. 9, 2013 - ACCESSWIRE
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma 8:00 a.m. Dec. 9, 2013 - PR Newswire
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 6:00 p.m. Dec. 8, 2013 - BusinessWire
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia 6:30 p.m. Dec. 7, 2013 - BusinessWire
U.S. Food and Drug Administration Approves Gilead's Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 4:19 p.m. Dec. 6, 2013 - BusinessWire
Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3 5:00 p.m. Dec. 2, 2013 - BusinessWire
Critical Alerts For General Electric, Gilead Sciences, Morgan Stanley, Qualcomm, and Adobe Released By InvestorsObserver 9:31 a.m. Dec. 2, 2013 - PR Newswire
Market Expert Opinion: Gilead Sciences, NPS Pharma, InterMune, and Halozyme Therapeutics 8:40 a.m. Dec. 2, 2013 - PR Newswire
Gilead Sciences, Inc. Uses the PHT Corporation LogPad(R) System for 1st Antianginal Drug to Treat Type 2 Diabetes 8:00 a.m. Dec. 2, 2013 - BusinessWire
Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits Against Gilead Sciences 7:00 a.m. Dec. 2, 2013 - GlobeNewswire
Early Morning Buzz: Groupon, Gilead Sciences, Eltek Ltd, Alcatel Lucent SA 9:47 a.m. Nov. 27, 2013 - ACCESSWIRE
Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare 8:00 a.m. Nov. 27, 2013 - PR Newswire
Clinical Studies, Convertible Senior Notes, and Commercial Supply Contracts - Research Report on Gilead, Hologic, Regeneron, OPKO, and Unilife 8:00 a.m. Nov. 25, 2013 - PR Newswire
European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi(R) for the Treatment of Chronic Hepatitis C Infection 8:47 a.m. Nov. 22, 2013 - BusinessWire
Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb, HCA, Allergan, and Alexion 8:00 a.m. Nov. 20, 2013 - PR Newswire
Gilead's Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study 9:17 a.m. Nov. 18, 2013 - BusinessWire
European Commission Approves Gilead's Vitekta(TM), an Integrase Inhibitor for the Treatment of HIV-1 Infection 8:00 a.m. Nov. 18, 2013 - BusinessWire
Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13 4:31 p.m. Nov. 12, 2013 - BusinessWire
Insider Trading Reports for Facebook, Microsoft, Gilead Sciences, Bank of America, Riverbed, and Wells Fargo 8:55 a.m. Nov. 11, 2013 - PR Newswire
S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
(0)
(0)Scroll down for more posts ▼